Inflammation enhances the effect of a genetic risk variant in schizophrenia

picture:

“This suggests that the mechanism we see in the lab is also relevant to patients’ brains and that inflammation enhances the effect of a genetic risk variant,” he says. Karl Silgren Magkowitza researcher in the Department of Physiology and Pharmacology, and chief medical officer of Psychiatry Nordfast, Stockholm Region, who led the study.

The researchers hope the findings will lead to more effective and targeted therapies for early-stage schizophrenia.

Currently available treatments are not individually tailored and focus on reducing symptoms for patients who already have the disease, says Karl Silgren Magkowitz.

The study was funded by the Swedish Research Council, the One Mind Foundation/Kaiser Permanente, the Erling Persson Foundation, the Marianne and Markus Wallenberg Foundation, as well as ALF funds.

Publishing

“Increased cerebrospinal fluid concentration of complement component 4a in the first episode of schizophrenia”. Jessica Gracias, Fonda Orhan, Elaine Horbik, Jessica Holmen-Larson, Nida Khanlarkani, Susmita Malwad, Saravan K. Gobaraju, Lily Schuyler, Elknor. Demirel, Ting Fu, Helena Vattoros-Bergmann, Orimantas Bilanes, Carlton B. Gold, Aneli Golding, Kristina Anerbrink, Agnella Esgren, Timea Spring, Martin Schalling, Viviana A. Karamo Yanez, Jens C. Goepvert, Johanna Nelson, Ann Brinkmalm, Plino, Henrik Zetterberg, Goran Ingberg, Frederick Bell, Stephen de Sheridan, Roy H. Perlis, Simon Cervenka, Sophie Erhardt, Michael Landin, Carl M. Connecting with naturesonline 3 Nov 2022, doi: 10.1038/s41467-022-33797-6